$15.97
+6.9%Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
SDGR • NASDAQ
| Schrödinger, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
REVENUE | |||||||||
255.9M | 207.5M | 216.7M | 181M | 137.9M | 108.1M | 85.5M | 66.6M | 55.7M | |
GROSS PROFIT | |||||||||
(113.3M) | (75.5M) | (76M) | (79.9M) | (72.3M) | (44.6M) | (36.5M) | (23.7M) | (15.9M) | |
142.6M | 132.1M | 140.7M | 101M | 65.6M | 63.5M | 49.1M | 42.9M | 39.8M | |
OPERATING INCOME | |||||||||
(309.5M) | (341.4M) | (318.1M) | (247.8M) | (177.1M) | (124.4M) | (87.8M) | (70.9M) | (58.8M) | |
(136.4M) | (139.6M) | (136.4M) | (121.5M) | (86.2M) | (59.7M) | (48.4M) | (36.4M) | (31.2M) | |
(173.1M) | (201.8M) | (181.8M) | (126.4M) | (90.9M) | (64.7M) | (39.4M) | (34.5M) | (27.7M) | |
-166.9M | -209.3M | -177.4M | -146.8M | -111.4M | -60.9M | -38.7M | -28M | -19M | |
PRE-TAX INCOME | |||||||||
(0.0) | (0.0) | (0.0) | (3K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
0.0 | 0.0 | 0.0 | 3.9M | 1.1M | 2.3M | 1.9M | 433K | 359K | |
64.6M | 23.6M | 220.4M | -2.3M | 10.6M | 34.6M | 12.7M | -379K | 2M | |
-102.3M | -185.7M | 42.9M | -149.1M | -100.8M | -26.3M | -26M | -28.3M | -17.1M | |
NET INCOME | |||||||||
(939K) | (1.4M) | (2.2M) | (63K) | (411K) | (345K) | -291K | (77K) | (332K) | |
-103.3M | -187.1M | 40.7M | -149.2M | -100.4M | -24.5M | -24.6M | -28.4M | -17.4M |
SDGR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 20, 2026 | May 18, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 05, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 05, 2026 | May 05, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | April 28, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 12, 2026 | March 06, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 25, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 25, 2026 | February 25, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 05, 2025 | November 05, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 05, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 08, 2025 | September 05, 2025 | 2025 |
Continue your SDGR research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.